Efalizumab
Links shared publicly online about this topic
FDA Alert: Raptiva (efalizumab)
drugs.com — “FDA Alert: Raptiva (efalizumab)” View full resource at drugs.com
Most Recently Shared on February 19, 2009 at 11:44 pm By:
FDA Alert - Raptiva (efalizumab) - http://tinyurl.com/bhdkfx
FDA Alert: Raptiva (efalizumab)
drugs.com — “FDA Alert: Raptiva (efalizumab)” View full resource at drugs.com
Most Recently Shared on April 8, 2009 at 11:49 pm By:
FDA Alert - Raptiva (efalizumab) - Genentech and FDA announce voluntary, phased withdrawal of Raptiva - http://tinyurl.com/ddwqf6
Allergy/Imm Medical News about Efalizumab
mdlinx.com — “Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases” View full resource at mdlinx.com
Most Recently Shared on June 21, 2010 at 11:43 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases: Journal of the Europea... http://bit.ly/c7sR4H #AI #mdlinx
IngentaConnect Efalizumab: Disseminated human papillomavirus infection treated w...
ingentaconnect.com — “IngentaConnect Efalizumab: Disseminated human papillomavirus infection treated w...” View full resource at ingentaconnect.com
Most Recently Shared on August 13, 2010 at 10:56 am By:
Efalizumab: Disseminated human papillomavirus infection treated with peginterferon -2b and ribavirin: case report:... http://bit.ly/arijKh
Monoclonal Antibody-Associated Progressive Multifocal Leucoencephalopathy in Patients Treated With Rituximab, Natalizumab, and Efalizumab - OncologySTAT
oncologystat.com — “Lancet Oncol. 2009 Aug 1;10(8):816-824 - Risk management is important in serendipitous cases of PML arising from treatment with monoclonal antibodies.” View full resource at oncologystat.com
Most Recently Shared on August 19, 2009 at 8:31 pm By:
OncologySTAT Health Site and Oncology
Review Article of the Week: Progressive Multifocal Leukoencephalopathy With Rituximab, Natalizumab and Efalizumab http://tinyurl.com/ku47mg
Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension
content.karger.com — “Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation of Efalizumab Suspension” View full resource at content.karger.com
Most Recently Shared on April 12, 2011 at 4:18 pm By:
Patients with Moderate to Severe Plaque Psoriasis: One Year after the European Medicines Agency Recommendation o... http://bit.ly/dIqZmc
Medical News: Raptiva Yanked from U.S. Market - in Product Alert, Prescriptions from MedPage Today
medpagetoday.com — “WHEELING, W.Va. -- The psoriasis drug efalizumab (Raptiva) will be removed from the U.S. market because of the risk of progressive multifocal leukoencephalopathy (PML), its manufacturer said today.” View full resource at medpagetoday.com
Most Recently Shared on April 9, 2009 at 11:42 am By:
Efalizumab Yanked from U.S. Market http://medpagetoday.com/13666
Medicine and Technology [part of HCPLive]: FDA: Raptiva Voluntary Withdrawal
medicineandtechnology.com — “Medicine and Technology [part of HCPLive]: FDA: Raptiva Voluntary Withdrawal” View full resource at medicineandtechnology.com
Most Recently Shared on May 27, 2009 at 11:32 pm By:
Joseph Kim, MD, MPH Doctor and Physician
@BodyNHealth Lots of concern over the safety of biologics because of Raptiva. FDA has been slow to approve new drugs http://bit.ly/11fpdH
A Senior Care Pharmacist's Blog: Raptiva Withdrawal
medisort.blogspot.com — “The Official Blog of MediSort Medication Consultants” View full resource at medisort.blogspot.com
Most Recently Shared on April 10, 2009 at 9:38 pm By:
Brian Wolstenholme PharmD, Doctor, Wellness Coach, and Pharmacist
Raptiva Withdrawal: Raptiva (efalizumab) is an immunosuppressive recombinant monoclonal antibody used in adult p.. http://twurl.nl/tcdj3i
Voluntary Withdrawal of Raptiva - MPR
empr.com — “Genentech announced a voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market.” View full resource at empr.com
Most Recently Shared on April 8, 2009 at 10:48 pm By:
MPR News: Voluntary Withdrawal of Raptiva: Genentech announced a voluntary withdrawal of the psoriasis .. http://tinyurl.com/dzymh2
FDA: Psoriasis drug may be linked to 3 deaths* | Booster Shots | Los Angeles Times
latimesblogs.latimes.com — “The Food and Drug Administration today warned American patients that it is investigating the possibility of a link between the psoriasis drug marketed as Raptiva (efalizumab) and at least three deaths caused by a rare brain infection called progressive multifocal...” View full resource at latimesblogs.latimes.com
Most Recently Shared on February 20, 2009 at 1:10 am By:
LA Times Health News Health News
FDA: Psoriasis drug may be linked to 3 deaths*: The Food and Drug Administration today warned American patients .. http://tinyurl.com/db3t9b
Makers of Raptiva Remove Psoriasis Drug From Market Due to PML Risks
usrecallnews.com — “Genentech, makers of the psoriasis drug Raptiva (efalizumab) have announced a voluntary withdrawal of the drug from the US market after learning of a rare but serious risk to patients taking the drug.” View full resource at usrecallnews.com
Most Recently Shared on April 8, 2009 at 10:51 pm By:
New Recall Alert: Makers of Raptiva Remove Psoriasis Drug From Market Due to PML Risks http://tinyurl.com/cant5q
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
